

Svante Vikingsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/467717/publications.pdf>

Version: 2024-02-01

53
papers

1,471
citations

377584

21
h-index

388640

36
g-index

54
all docs

54
docs citations

54
times ranked

2843
citing authors

#	ARTICLE	IF	CITATIONS
1	Conversion of 7-Carboxy-Cannabidiol (7-COOH-CBD) to 11-Nor-9-Carboxy-Tetrahydrocannabinol (THC-COOH) during Sample Preparation for GC-MS Analysis. <i>Journal of Analytical Toxicology</i> , 2022, 46, 573-576.	1.7	7
2	The metabolism of the synthetic cannabinoids ADB-49-BUTINACA and ADB-49-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons. <i>Drug Testing and Analysis</i> , 2022, 14, 634-652.	1.6	30
3	Characterization of recent non-fentanyl synthetic opioids via three different in vitro μ -opioid receptor activation assays. <i>Archives of Toxicology</i> , 2022, 96, 877-897.	1.9	10
4	Prevalence of Cannabidiol, Δ^9 - and Δ^8 -Tetrahydrocannabinol and Metabolites in Workplace Drug Testing Urine Specimens. <i>Journal of Analytical Toxicology</i> , 2022, 46, 866-874.	1.7	2
5	Update on Urine Adulterants and Synthetic Urine Samples to Subvert Urine Drug Testing. <i>Journal of Analytical Toxicology</i> , 2022, 46, 697-704.	1.7	3
6	Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards. <i>Journal of Analytical Toxicology</i> , 2021, 44, 993-1003.	1.7	12
7	Activation of the μ -opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure. <i>Drug Testing and Analysis</i> , 2021, 13, 169-174.	1.6	7
8	Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 52-65.	1.2	8
9	Post-Mortem Metabolomics: A Novel Approach in Clinical Biomarker Discovery and a Potential Tool in Death Investigations. <i>Chemical Research in Toxicology</i> , 2021, 34, 1496-1502.	1.7	11
10	Circumstances, Postmortem Findings, Blood Concentrations and Metabolism in a Series of Methoxyacetylfentanyl-Related Deaths. <i>Journal of Analytical Toxicology</i> , 2021, 45, 760-771.	1.7	6
11	Metabolism of the benzodiazepines norflurazepam, flurazepam, fludiazepam and cinolazepam by human hepatocytes using high-resolution mass spectrometry and distinguishing their intake in authentic urine samples. <i>Forensic Toxicology</i> , 2020, 38, 79-94.	1.4	6
12	5F-MDMB-PICA metabolite identification and cannabinoid receptor activity. <i>Drug Testing and Analysis</i> , 2020, 12, 127-135.	1.6	41
13	Femoral blood concentrations of flualprazolam in 33 postmortem cases. <i>Forensic Science International</i> , 2020, 307, 110101.	1.3	28
14	Biotransformation of the New Synthetic Cannabinoid with an Alkene, MDMB-4en-PINACA, by Human Hepatocytes, Human Liver Microsomes, and Human Urine and Blood. <i>AAPS Journal</i> , 2020, 22, 13.	2.2	25
15	Metabolite Profiling of Ortho-, Meta- and Para-Fluorofentanyl by Hepatocytes and High-Resolution Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2020, 44, 140-148.	1.7	10
16	In vitro characterization of new psychoactive substances at the μ -opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. <i>Forensic Science International</i> , 2020, 317, 110553.	1.3	10
17	The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00581.	1.1	3
18	Metabolism of MMB022 and identification of dihydrodiol formation in vitro using synthesized standards. <i>Drug Testing and Analysis</i> , 2020, 12, 1432-1441.	1.6	12

#	ARTICLE	IF	CITATIONS
19	LC-QTOF-MS Identification of Major Urinary Cyclopropylfentanyl Metabolites Using Synthesized Standards. <i>Journal of Analytical Toxicology</i> , 2019, 43, 607-614.	1.7	14
20	Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1704-1709.	1.1	8
21	Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS. <i>Archives of Toxicology</i> , 2019, 93, 95-106.	1.9	24
22	Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway. <i>Drug Testing and Analysis</i> , 2018, 10, 1270-1279.	1.6	14
23	Synthesis and identifications of potential metabolites as biomarkers of the synthetic cannabinoid AKB-48. <i>Tetrahedron</i> , 2018, 74, 2905-2913.	1.0	11
24	A reassessment of DNA-immunoprecipitation-based genomic profiling. <i>Nature Methods</i> , 2018, 15, 499-504.	9.0	92
25	Fatal Poisonings Associated with New Psychoactive Substances. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 495-541.	0.9	40
26	Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. <i>AAPS Journal</i> , 2017, 19, 736-742.	2.2	30
27	Synthesis and identification of an important metabolite of AKB-48 with a secondary hydroxyl group on the adamantyl ring. <i>Tetrahedron Letters</i> , 2017, 58, 1456-1458.	0.7	6
28	Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3749-3756.	1.9	8
29	In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl. <i>AAPS Journal</i> , 2017, 19, 1102-1122.	2.2	76
30	Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. <i>Forensic Science International</i> , 2017, 274, 55-63.	1.3	28
31	Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells – Effects on gene expression levels and thiopurine metabolism. <i>PLoS ONE</i> , 2017, 12, e0173825.	1.1	6
32	In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 230-238.	1.0	11
33	Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. <i>Drug Testing and Analysis</i> , 2016, 8, 950-956.	1.6	40
34	Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm. <i>Atherosclerosis</i> , 2016, 249, 101-109.	0.4	33
35	Novel rapid liquid chromatography tandem massspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state. <i>Biomedical Chromatography</i> , 2016, 30, 1234-1239.	0.8	6
36	Differences in cardiovascular toxicities associated with cigarette smoking and snuff use revealed using novel zebrafish models. <i>Biology Open</i> , 2016, 5, 970-978.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Putting Designer Drugs Back in Pandora's Box: Analytical Challenges and Metabolite Identification. <i>Clinical Chemistry</i> , 2016, 62, 4-5.	1.5	4
38	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 366-373.	3.2	20
39	A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 186-195.	1.4	25
40	Identification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2015, 39, 426-435.	1.7	46
41	Increased <i>Rrm2</i> gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. <i>Genes and Development</i> , 2015, 29, 690-695.	2.7	51
42	Role of cytochrome P450 <i>CYP2C8</i> in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , 2015, 16, 929-937.	0.6	17
43	Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1702-1709.	0.6	11
44	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 52-61.	0.7	34
45	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. <i>Nature</i> , 2014, 508, 215-221.	13.7	419
46	Monitoring of thiopurine metabolites – A high-performance liquid chromatography method for clinical use. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 75, 145-152.	1.4	20
47	Expression Patterns of 17 β -Hydroxysteroid Dehydrogenase 14 in Human Tissues. <i>Hormone and Metabolic Research</i> , 2012, 44, 949-956.	0.7	21
48	Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 495-504.	1.9	15
49	The Role of Inosine-5'-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 200-208.	1.0	23
50	A validated and rapid high-performance liquid chromatography method for the quantification of conversion of radio-labelled sex steroids. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 3, 375-81.	0.3	0
51	How Should Thiopurine Treatment be Monitored? Methodological Aspects. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010, 29, 278-283.	0.4	5
52	Monitoring of Thiopurine Metabolites in Patients With Inflammatory Bowel Disease-What Is Actually Measured?. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 345-350.	1.0	28
53	Retention of opioids and their glucuronides on a combined zwitterion and hydrophilic interaction stationary phase. <i>Journal of Chromatography A</i> , 2008, 1187, 46-52.	1.8	28